Novartis International AG
EU lobbying footprint — who they meet, and on what. Built only from official disclosures, every meeting cited.
Novartis International AG has 89 disclosed EU lobbying meetings from 2024-10-03 to 2026-07-08: 18 with the European Commission and 71 with Members of the European Parliament. Source: EU Transparency Register no. 91269481588-28, Commission disclosures and MEP declarations.
Lobbying profile
as declared 2026-03-10- Category
- Companies & groups
- Legal status
- Corporation
- Declared lobbying cost
- €2,500,000
- Lobbying FTEs
- 3.25
- Members
- 5
Files it’s lobbying on
The org's disclosed policy areas, ranked by number of meetings.
Declared fields of interest
Borders and security · Business and industry · Competition · Consumers · Customs · Digital economy and society · Economy, finance and the euro · Employment and social affairs · Environment · External relations · Institutional affairs · International co-operation and development
At a glance
The officials and MEPs most often met, by disclosed-meeting count.
- Olivér Várhelyi3
- Laszlo Kristoffy1
- Carmen Laplaza Santos1
- Jana Dabbelt1
- Vincenzo Matano1
Disclosed meetings
Newest first, showing the most recent 60 of 89. EC = European Commission, EP = Member of the European Parliament.
- Biotech Act Isource ↗
- Competitividade europeia, investigação e inovação, reforço do Mercado Único e a agenda de segurança económicasource ↗
- Biotechnology Innovation, Health Policy and European Competitiveness (2025/0406(COD) – European Biotech Act)source ↗
- IMCO opinion on MDR/IVDR filesource ↗
- Biotech Actsource ↗
- Annual meeting with Slovenian pharmaceutical industrysource ↗
- Biotechnology Innovation, Health Policy and European Competitivenesssource ↗
- Apresentação do contributo e as principais iniciativas da Novartis em Portugalsource ↗
- BIOTECH ACTsource ↗
- Biotech Actsource ↗
- biotechsource ↗
- Diff. SANT topicsource ↗
- Biotechsource ↗
- Biotech Isource ↗
- Discussion on Irish bio-tech state of playsource ↗
- Biotech Actsource ↗
- European Competitiveness from medicine perspectivesource ↗
- Biotech Act Isource ↗
- Biotech Act Isource ↗
- Geneeskundesource ↗
- 2026-05-07ECLaszlo Kristoffy · Cabinet of Commissioner Olivér VárhelyiRoundtable on the health packagesource ↗
- Biotech Actsource ↗
- Biotech Act Isource ↗
- Intro meetingsource ↗
- Biotech Actsource ↗
- Exchange of views on Cardiovascular Strategysource ↗
- 2026-02-03ECCarmen Laplaza Santos · Head of UnitExchange of views on the competitiveness of the European pharmaceutical sector.source ↗
- 2026-01-21ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiHealth Packagesource ↗
- 2025-12-02ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiPharma affairssource ↗
- Pharmaceutical legislationsource ↗
- Radioligand Therapy (RLT)source ↗
- Innovative Technologien der Pharmaindustriesource ↗
- 2025-10-02ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiAll pressing portfolio topicssource ↗
- Critical Medicines Actsource ↗
- Health policysource ↗
- 2025-09-17ECVincenzo Matano · Cabinet of Executive Vice-President Raffaele FittoIntroductory Meeting on Coalizione VITA Activitiessource ↗
- Pharmaceuticalssource ↗
- 2025-09-04ECVilija Sysaite · Cabinet of Executive Vice-President Stéphane SéjournéEuropean competitiveness aspectssource ↗
- Prioridades en salud públicasource ↗
- Pharma Industry, Competitivenesssource ↗
- EU Pharmasource ↗
- Pharmaceutical regulationsource ↗
- Revision of pharmaceutical legislation and the Omnibus Regulationssource ↗
- Introductory Meetingsource ↗
- Pharmaceutical policysource ↗
- Exchange of views on future legislationsource ↗
- Pharmaceutical Legislationsource ↗
- Risks & Opportunities for the Romanian Pharmaceutical Sectorsource ↗
- 2025-06-03ECMaya Matthews · Head of UnitThe role of the Commission was here to facilitate the exchange between Novartis and the HTA Coordination Group Chairs about a medicinal product sent for joint clinical assessmentsource ↗
- Radioligandossource ↗
- 2025-05-26ECBernardus Zuijdendorp · Head of UnitExchange of views on the need and prospects for simplification in Pillar 2, in particular in light of the current situation with the USsource ↗
- 2025-05-26ECKatarina Koszeghy · Cabinet of Commissioner Wopke HoekstraExchange of views on the need and prospects for simplification in Pillar 2, in particular in light of the current situation with the USsource ↗
- 2025-05-13ECLaurent Muschel · DirectorBilateral meeting between Novartis and HERA on international coordination, legislation, innovationsource ↗
- 2025-04-11ECHoa-Binh Adjemian · Head of UnitEngagement regarding Novartis activities in Serbia and signature of an MoU with the Serbian Governmentsource ↗
- Introduction, exchange of viewssource ↗
- 2025-03-15ECAxel Hellman · Cabinet of Commissioner Jessika RoswallImpact of EU environmental policies on the life science sectorsource ↗
- Politique de santé de l'Union européennesource ↗
- 2025-03-11ECAna Rita Lopes Ramos · Head of UnitDiscussion on Supporting Therapeutic Radiopharmaceuticals Innovationsource ↗
- 2025-02-26ECOlivér Várhelyi · Cabinet of Commissioner Olivér VárhelyiHealthcare, biotech and agri-food policiessource ↗
- 2025-02-18ECKatri Teedumäe · Cabinet of Commissioner Olivér VárhelyiEU health policysource ↗
Frequently asked
How many EU lobbying meetings has Novartis International AG disclosed?
Novartis International AG (EU Transparency Register no. 91269481588-28) appears in 89 disclosed meetings with EU officials and MEPs between 2024-10-03 and 2026-07-08: 18 with the European Commission and 71 with Members of the European Parliament.
What does Novartis International AG lobby on?
Novartis International AG's disclosed EU meetings most often concern Health, Technology. Every meeting and its topic is listed with its official source on this page.
Who does Novartis International AG meet in Brussels?
Across its disclosed meetings, Novartis International AG has met Commission officials including Olivér Várhelyi, Laszlo Kristoffy, Carmen Laplaza Santos, and MEPs including MANDL Lukas, FERENC Viktória, NEVADO DEL CAMPO Elena. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Related on the graph
The same footprint, mapped onto the topics and files it touches.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.
See your company’s overlap with Novartis International AG — and the rest of the corpus.
Enter your company and Lex builds a cited Exposure Map in about 30 seconds. Free, no login.